J & J arthritis drug sirukumab raises safety concerns: FDA staff
(Reuters) - Staff reviewers for the U.S. Food and Drug Administration noted on Monday that there was a trend of increased death with Johnson& Johnson's experimental rheumatoid arthritis drug sirukumab compared with placebo.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Arthritis | Food and Drug Administration (FDA) | Health | Rheumatoid Arthritis | Rheumatology